| Ytd | 10.32% | |
| 1y | 65.94% |
| Open | 46.07 | Prev Close | 46.27 | Low | 45.72 | High | 46.67 | Mkt Cap | 3.71B |
| Vol | 312.52K | Avg Vol | 1.32M | EPS | 2.00 | P/E | 23.23 | Forward P/E | 24.24 |
| Beta | 1.95 | Short Ratio | 4.77 | Inst. Own | 112.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 53.41 | 200-d Avg | 42.21 | 1yr Est | 57.82 |
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evide
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Est
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a lead
First Trust Advisors LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 64.9% in the
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnin
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification a
Fifth Third Bancorp boosted its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 10,285.2% dur
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approac
Amova Asset Management Americas Inc. lessened its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) b
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Gr
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and
Piper Sandler analyst David Westenberg initiates coverage on Veracyte (NASDAQ:VCYT) with a Overwe
Canaccord Genuity analyst Kyle Mikson maintains Veracyte (NASDAQ:VCYT) with a Hold and raises the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagno
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about
Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transactio
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, internat
A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50
Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its
Gainers
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
On Wednesday, 807 companies reached new 52-week lows.
During Thursday, 351 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to repo
During Thursday, 849 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to repo
During Friday's session, 445 companies made new 52-week lows.